08 dec: Vestas-aktien ramt af Trump-udnævnelse af ny chef for EPA
08 dec: TDC vil købe obligationer tilbage for at reducere gæld - NY
08-12-2016 10:35:35

Zealand increases its share capital as a consequence of exercise of employee warrants

Relateret indhold
08 feb - 
Aktier/tendens: Tunge regnskaber fra bl.a. Mærsk, Vesta..
08 feb - 
Sanofi leverer resultat på linje med forventningerne - ..
06 feb - 
Zealand Pharma: Patienter med tarmsygdom rekrutteret ti..
Relateret debat
19:37 - 
Og hvad er det du vil fortælle ?
18:50 - 
Eller året efter, men han kunne have lyttet til t..
18:49 - 
Indlæg af : alpehue   (  Tilf&osla..

Company announcement - No. 49 / 2016

Zealand increases its share capital as a consequence of exercise of employee warrants

Copenhagen, 8 December 2016 - Zealand Pharma ("Zealand") has increased its share capital with nominal DKK 13,999 divided into 13,999 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under one of Zealand's employee warrant programs. Employee warrant programs are part of Zealand's incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand share at a pre-specified price, the exercise price, in specific pre-defined time periods before expiration. For further description of Zealand's warrant programs, see the company's Articles of Association, which are available on the homepage: www.zealandpharma.com.

The exercise price is DKK 77 and the total proceeds to Zealand from the capital increase amounts to DKK 1,077,923.

The new shares give rights to dividend and other rights from the time of the warrant holder's exercise notice. Each new share carries one vote at Zealand's general meetings. Zealand only has one class of shares.

The new shares will be listed on Nasdaq Copenhagen after registration of the capital increase with the Danish Business Authority. Following registration of the new shares, the share capital of Zealand will be nominal DKK 26,142,365 divided into 26,142,365 shares with a nominal value of DKK 1 each.

The amendment of Zealand's Articles of Association entailed by the share capital increase has today been registered with the Danish Business Authority.

*****

For further information, please contact:

Mats Blom,

Senior Vice President, Chief Financial Officer

Tel: +45 31 53 79 73, email:mabl@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under licence collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of proprietary product candidates which primarily target specialty diseases with significant unmet needs.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia® outside the United States and approved as Adlyxin(TM) in the United States. Lixisenatide has been developed in a fixed-ratio combination with basal insulin glargine (Lantus®) and is approved as Soliqua(TM) 100/33 in the United States, and in Europe a CHMP positive opinion recommendation was given in November (Suliqua(TM) is the brand name in Europe).  

Zealand's proprietary pipeline includes: Dasiglucagon* (ZP4207) (single-dose rescue treatment) for acute, severe hypoglycaemia (Phase II); Glepaglutide* (ZP1848) for short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) (multiple-dose version) intended for use in a dual-hormone artificial pancreas system for better hypoglycaemia control and diabetes management (in preparation for Phase II); and other earlier stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and Glepaglutide are proposed International Nonproprietary Names (pINN).

49-16_1208 Warrant exercise and capital increase


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Zealand Pharma via Globenewswire

Vedhæftet fil: 774036.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
03:31
ZEAL
Jeg er sådan set enig med Alpehue mht. salgspotentiale, det er et godt bud på topsalg efter min meni..
5
25 feb
ZEAL
Er det ikke det, man kalder skønne spildte kræfter, alpehue - de fleste husker nok dine tilsvarende ..
5
21 feb
ZEAL
.. og dem bliver der flere og flere af.    Her er hvad der er rapporteret online 10. feb. i Diabetes..
5
25 feb
ZEAL
alpe ved temmelig meget om diabetes, giv dog manden noget kredit istedet for altid at nedgøre ham, d..
4
25 feb
ZEAL
Zealand Pharma afrapportering af fase 2-programmer + salgstal på Soliqua   Som bekendt så står Zeala..
4
23 feb
ZEAL
Kære Eliot. Vent på årsrapporten og en muligvis reorganisering. Fakta og aktion er det eneste der..
4
24 feb
ZEAL
Nu er de 332 Soliqua recepter i de første 5 uger jo i skrivende stund ikke dokumenteret andet end på..
3
23 feb
ZEAL
Jeg tror I/vi må have mere tålmodighed end det synes at være tilfældet her på sitet. Jeg har modtage..
3
12:20
ZEAL
stop nu jer selv - sited bliver jo mere og mere ødelagt, mvh. Henrik 
2
25 feb
ZEAL
Trendlæsning for begyndere - ingen grund til at gøre det nemme svært !.   Den omtalte optrend fra fe..
2

Rovsing mindsker driftsunderskud i første halvår og opjusterer

24-02-2017 16:36:15
Omsætningen i Rovsing, der har hovedkontor i Skovlunde ved København og blandt andet producerer testsystemer til satellitter og elektroniske produkter til rumin..

KORR. Genmab/Sydbank: Positiv anbefaling er godt nyt - og ventet

24-02-2017 14:04:12
(Korr: "uger" rettet til "måneder" i sjette afsnit)Det europæiske lægemiddelagenturs (EMA) komite for medicinske produkter for human anvendelse (CHMP) har givet..

Aktier/middag: Mærsk og Genmab i C20-bunden og dukkert til Rockwool

24-02-2017 11:44:51
Trods yderligere fremgang til ISS, der torsdag leverede et stærkt regnskab, ligger det danske aktiemarked fredag middag i et minus efter fald i aktier som Mærsk..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Zealand Pharma A/S 116,50 -1,7% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. februar 2017 20:04:30
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170217.2 - EUROWEB5 - 2017-02-26 20:04:30 - 2017-02-26 20:04:30 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x